Invirase and Pentacarinat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Invirase (saquinavir mesylate) and Pentacarinat (pentamidine isethionate). Common drug interactions include pregnancy among females and blindness among males.

The phase IV clinical study analyzes what interactions people have when they take Invirase and Pentacarinat. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Invirase?

Invirase has active ingredients of saquinavir mesylate. eHealthMe is studying from 2,690 Invirase users. Check the latest studies of Invirase.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.



On Jul, 12, 2026

19 people who take Invirase and Pentacarinat together, and have interactions are studied.

Invirase and Pentacarinat drug interactions.

What are the common drug interactions of Invirase and Pentacarinat, by gender? *:

female:

  1. Pregnancy
  2. Diarrhoea
  3. Abortion spontaneous (naturally occurring miscarriage)
  4. Agitation (state of anxiety or nervous excitement)
  5. Anaemia neonatal
  6. Dystonia (abnormal muscle tone)
  7. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  8. Muscle contractions involuntary (uncontrolled muscle contraction)
  9. Salivary hypersecretion (excess saliva secretion)
  10. Urinary tract disorder

male:

  1. Blindness
  2. Cerebral infarction (less blood supply to brain resulting tissue damage)
  3. Hemianopia (blindness or reduction in vision in one half of the visual field due to damage of the optic pathways in the brain)
  4. Abnormal behaviour
  5. Injury
  6. Visual acuity reduced (reduced clearness of vision)
  7. Visual disturbance

What are the common drug interactions of Invirase and Pentacarinat, by age (0-1 to 60+)? *:

0-1:

  1. Agitation (state of anxiety or nervous excitement)
  2. Blood lactic acid increased
  3. Dystonia (abnormal muscle tone)
  4. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  5. Muscle contractions involuntary (uncontrolled muscle contraction)
  6. Tongue coated
  7. Anaemia (lack of blood)
  8. Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
  9. Anaemia neonatal
  10. Pregnancy

2-9:

n/a

10-19:

n/a

20-29:

  1. Anaemia (lack of blood)
  2. Diarrhoea
  3. Urinary tract disorder
  4. Anogenital warts
  5. Dysuria (painful or difficult urination)
  6. Pregnancy
  7. Salivary hypersecretion (excess saliva secretion)
  8. Urinary tract infection
  9. Vomiting
  10. Culture urine positive

30-39:

  1. Abortion spontaneous (naturally occurring miscarriage)
  2. Blood lactic acid increased
  3. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  4. Hepatotoxicity (chemical-driven liver damage)
  5. Injury
  6. Lactic acidosis (low ph in body tissues)
  7. Platelet count decreased
  8. Pregnancy
  9. Visual acuity reduced (reduced clearness of vision)
  10. Visual disturbance

40-49:

n/a

50-59:

  1. Completed suicide (act of taking one's own life)

60+:

n/a

What are the existing conditions these people have? *

  1. Hiv Infection: 4 people, 21.05%
  2. Unevaluable Reaction: 1 person, 5.26%
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Invirase and Pentacarinat?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Invirase and Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Invirase:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Invirase and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentacarinat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on saquinavir mesylate and pentamidine isethionate (the active ingredients of Invirase and Pentacarinat, respectively), and Invirase and Pentacarinat (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: